Several studies have shown that E-cadherin down-regulation is important in cancer progression and is associated with poor outcome in several tumor sites, including non-small cell lung cancer, invasive ductal breast carcinoma, and gastric adenocarcinoma [43,44]. This evidence concerns the gene CDH1 and non-small cell lung carcinoma.